论文部分内容阅读
诺华公司新嵌合式抗体受体CTL019的长期临床治疗资料显示,39名儿科复发性难治性急性淋巴母细胞白血病患者中有36名,即92%的患者病情获得完全缓解。急性淋巴母细胞白血病是儿童最常见恶性血液病,在15岁以下癌症患儿中达25%,成年人也可发生。患者骨髓中产生大量异常淋巴细胞,诊断后若不及时治疗,病情可迅速恶化,导致患者在数月内死亡。CTL019使用嵌合式抗体受体技术使患者的T细胞重新编程,以猎杀表达特异CD19蛋白的癌细胞。重新编程的T细胞称为CTL019,进入血液增殖后,靶向CD19癌
The long-term clinical data of Novartis’s new chimeric antibody receptor CTL019 showed that 36 out of 39 pediatric patients with relapse-prone and acute lymphoblastic leukemia, or 92% of patients, achieved complete remission. Acute lymphoblastic leukemia is the most common hematological malignancy in children, up to 25% in children under the age of 15 and adults can also develop. A large number of abnormal lymphocytes are produced in the patient’s bone marrow. If the patient is not treated promptly after diagnosis, the condition can rapidly deteriorate, causing the patient to die within a few months. CTL019 uses chimeric antibody receptor technology to reprogram the patient’s T cells to kill cancer cells that express the specific CD19 protein. The reprogrammed T cells are called CTL019 and enter the blood to target CD19